Adma Biologics (ADMA) Income from Continuing Operations (2011 - 2026)
Adma Biologics' (ADMA) quarterly Income from Continuing Operations came in at 133277000.0 in Q4 2025, down 367.26% YoY from 49868000.0 in Q4 2024, and down 465.86% on a QoQ basis from 36428000.0 in Q3 2025.
Adma Biologics (ADMA) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 13 years of Income from Continuing Operations data on file, last reported at 133277000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 367.26% year-over-year to 133277000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 35726000.0 (down 126.34% YoY) and the FY2025 annual result came in at 35726000.0, down 126.34% from the prior year.
- Income from Continuing Operations slipped to 133277000.0 in Q4 2025, from 36428000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 49868000.0 in Q4 2024 to a low of 133277000.0 in Q4 2025.
- A 5-year average of 1353055.5 and a median of 6580000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations surged 1299.96% — and 2025, when it slumped 367.26%.
- Tracing ADMA's Income from Continuing Operations over 5 years: stood at 13488684.0 in 2021, then climbed by 12.57% to 11792616.0 in 2022, then jumped by 189.84% to 10594000.0 in 2023, then surged by 370.72% to 49868000.0 in 2024, then slumped by 367.26% to 133277000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 133277000.0 (Q4 2025), 36428000.0 (Q3 2025), and 34219000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 37.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.82 Mn |
| Dec 31, 2025 | -133.28 Mn |
| Sep 30, 2025 | 36.43 Mn |
| Jun 30, 2025 | 34.22 Mn |
| Mar 31, 2025 | 26.90 Mn |
| Dec 31, 2024 | 49.87 Mn |
| Sep 30, 2024 | 35.91 Mn |
| Jun 30, 2024 | 32.06 Mn |
| Mar 31, 2024 | 17.81 Mn |
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 2.57 Mn |
| Jun 30, 2023 | -6.37 Mn |
| Mar 31, 2023 | -6.79 Mn |
| Dec 31, 2022 | -11.79 Mn |
| Sep 30, 2022 | -14.89 Mn |
| Jun 30, 2022 | -13.75 Mn |
| Mar 31, 2022 | -18.17 Mn |
| Dec 31, 2021 | -13.49 Mn |
| Sep 30, 2021 | -17.73 Mn |
| Jun 30, 2021 | -18.82 Mn |